ATXSAstria Therapeutics, Inc.

ATXS Stock Price, Valuation & Chart | Astria Therapeutics, Inc.

Compare

$12.580+0.00 (+0.00%)

At close · 23 Jan 2026, 09:00 pm

Sector: Healthcare Industry: Biotechnology ATXS intrinsic value ATXS calculated fair value vs price

Overview Financials Dividends Ratios

ATXS Historical price chart

ATXS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization718.13M

PE Ratio-5.88

EPS-2.14

Trading Volume3.06M

Today's High/Low12.58/12.58

Dividend Yield0.00

52 Week High/Low13.29/3.56

Shares Outstanding57.08M

ATXS Financial Statement

ATXS Analyst ratings

ATXS Analysis & performance metrics

ATXS Company profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and…

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary…

ATXS Management team

Name

Position

Christopher J. Morabito M.D.

Chief Medical Officer

Andrew A. Komjathy

Chief Commercial Officer

Keri McGrail

Chief Human Resources Officer

Andrea L. Matthews

Chief Business Officer

John Ruesch

Senior Vice President of Pharmaceutical Sciences & Technical Operations

Noah C. Clauser CPACFO

Chief Financial Officer & Treasurer

Rafif Dagher

Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research

Benjamin S. Harshbarger J.D.

Chief Legal Officer

Name

Position

Christopher J. Morabito M.D.

Chief Medical Officer

Andrew A. Komjathy

Chief Commercial Officer

Keri McGrail

Chief Human Resources Officer

Andrea L. Matthews

Chief Business Officer

John Ruesch

Senior Vice President of Pharmaceutical Sciences & Technical Operations

Noah C. Clauser CPACFO

Chief Financial Officer & Treasurer

Rafif Dagher

Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research

Benjamin S. Harshbarger J.D.

Chief Legal Officer

Management Team

Christopher J. Morabito M.D.

Chief Medical Officer

Andrew A. Komjathy

Chief Commercial Officer

Keri McGrail

Chief Human Resources Officer

Andrea L. Matthews

Chief Business Officer

John Ruesch

Senior Vice President of Pharmaceutical Sciences & Technical Operations

Noah C. Clauser CPACFO

Chief Financial Officer & Treasurer

Rafif Dagher

Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research

Benjamin S. Harshbarger J.D.

Chief Legal Officer

Management

Christopher J. Morabito M.D.

Chief Medical Officer

Andrew A. Komjathy

Chief Commercial Officer

Keri McGrail

Chief Human Resources Officer

Andrea L. Matthews

Chief Business Officer

John Ruesch

Senior Vice President of Pharmaceutical Sciences & Technical Operations

Noah C. Clauser CPACFO

Chief Financial Officer & Treasurer

Rafif Dagher

Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research

Benjamin S. Harshbarger J.D.

Chief Legal Officer

Total 8 executives

ATXS Frequently asked questions

What is Astria Therapeutics, Inc. (ATXS) Stock Price?

Current stock price of Astria Therapeutics, Inc. (ATXS) stock is $12.580. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Astria Therapeutics, Inc. (ATXS) stock is 3.06M.

Last updated at 23 Jan 2026, 09:00 pm.

Why is the Astria Therapeutics, Inc. (ATXS) stock price going up or down today?

The stock price of Astria Therapeutics, Inc. (ATXS) can change with earnings, company news, and overall market sentiment. Astria Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Astria Therapeutics, Inc. stock expensive at its current price?

Whether Astria Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ATXS on this page is -5.88. EPS on this page is -2.14. Compare those figures with peers and growth expectations before deciding if the current Astria Therapeutics, Inc. price is justified.

How has the stock price of Astria Therapeutics, Inc. (ATXS) performed historically?

Historical performance for Astria Therapeutics, Inc. (ATXS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ATXS reacted to past earnings and market events.

Should I buy Astria Therapeutics, Inc. (ATXS) stock, at this price?

Buying Astria Therapeutics, Inc. (ATXS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.